India’s first nasal vaccine by Bharat Biotech gets drug panel’s nod for ‘restricted use’

0

The Central Drugs Standard Control Organisation has approved the vaccine for primary immunisation against COVID-19 in the above 18 age group for ‘restricted use in an emergency situation’

Representational image. PTI

New Delhi: A nasal vaccine against COVID-19, developed by Covaxin-maker Bharat Biotech has been approved for “restricted use” by India’s top drug controller, Union health minister Mansukh Mandaviya said on Tuesday.

The Central Drugs Standard Control Organisation has approved the vaccine for primary immunisation against COVID-19 in the above 18 age group for “restricted use in an emergency situation.”

The union health minister also said that India has harnessed its science, R&D, and human resources in the fight against COVID-19 under PM Narendra Modi’s leadership.

According to a News18 report, in August, Bharat Biotech International Limited (BBIL) said that its COVID-19 intranasal vaccine (BBV154) has proven to be safe, well-tolerated, and immunogenic in subjects in controlled phase-3 clinical trials.

The trials were conducted with the help of nearly 4,000 volunteers, the report added.

With inputs from agencies

Read all the Latest News, Trending NewsCricket News, Bollywood News,
India News and Entertainment News here. Follow us on Facebook, Twitter and Instagram.

FOLLOW us ON GOOGLE NEWS

 

Read original article here

Denial of responsibility! My droll is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – [email protected]. The content will be deleted within 24 hours.

Leave a comment